Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/emmm.201505262 http://scihub22266oqcxt.onion/10.15252/emmm.201505262 C4604679!4604679!26202382     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EMBO+Mol+Med 2015 ; 7 (10): 1248-50 Nephropedia Template TP {{tp|p=26202382|t=2015. Compassionate use of experimental therapies: who should decide?|pdf=|usr=}}{{26202382}} gab.com Text Compassionate use of experimental therapies: who should decide JO: EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=26202382 #FOAvip In addition to being an example of unsubstantiated hype about regenerative medicine, the controversy around the Italy-based Stamina Foundation's unproven stem cell therapy represents another chapter in a continuing debate about how to balance patients' requests for early access to experimental medicines with requirements for demonstrating safety and effectiveness. Compassionate use of the Stamina therapy arguably should not have been permitted under Italy's laws, but public pressure was intense and judges ultimately granted access. One lesson from these events is that expert regulatory agencies may be the institutions most competent to make compassionate use decisions and that policies should include more specific criteria for authorizing compassionate use. But even where regulatory agencies make decisions based on clear rules, difficult questions will arise. Twit Text FOAVip Compassionate use of experimental therapies: who should decide ????EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=26202382 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26202382 #FOAvip English Wikipedia <ref>{{Cite pmid|26202382}}</ref> Compassionate use of experimental therapies: who should decide? #MMPMID26202382 Zettler PJ EMBO Mol Med 2015[Oct]; 7 (10): 1248-50 PMID26202382show ga In addition to being an example of unsubstantiated hype about regenerative medicine, the controversy around the Italy-based Stamina Foundation's unproven stem cell therapy represents another chapter in a continuing debate about how to balance patients' requests for early access to experimental medicines with requirements for demonstrating safety and effectiveness. Compassionate use of the Stamina therapy arguably should not have been permitted under Italy's laws, but public pressure was intense and judges ultimately granted access. One lesson from these events is that expert regulatory agencies may be the institutions most competent to make compassionate use decisions and that policies should include more specific criteria for authorizing compassionate use. But even where regulatory agencies make decisions based on clear rules, difficult questions will arise. äCompassionate use of experimental therapies: who should decide?(epmc).pdf DeepDyve Pubget Overpricing